Muscle loss is common in advanced lung cancer, impairing quality of life and shortening life expectancy. The impact of cancer on muscle metabolism has not been well explored. The effects of late-stage nonesmall-cell lung cancer on key metabolic processes in muscle was studied. Changes consistent with impaired synthesis of new muscle proteins and reduced lipid storage were observed. Introduction: The loss of muscle is common in patients with advanced nonesmall-cell lung cancer (NSCLC) and contributes to the high morbidity and mortality of this group. The exact mechanisms behind the muscle loss are unclear. Patients and Methods: To investigate this, 4 patients with stage IV NSCLC who met the clinical definitions for sarcopenia and cachexia were recruited, along with 4 age-matched healthy volunteers. After an overnight fast, biopsy specimens were obtained from the vastus lateralis, and the key components associated with inflammation and the control of muscle protein, carbohydrate, and fat metabolism were assessed. Results: Compared with the healthy volunteers, significant increases in mRNA levels for interleukin-6 and NF-kB signaling and lower intramyocellular lipid content in slow-twitch fibers were observed in NSCLC patients. Although a significant decrease in phosphorylation of the mechanistic target of rapamycin (mTOR) signaling protein 4E-BP1 (Ser 65 ) was observed, along with a trend toward reduced p70 S6K (Thr 389 ) phosphorylation (P ¼ .06), no difference was found between groups for the mRNA levels of MAFbx (muscle atrophy F box) and MuRF1 (muscle ring finger protein 1), chymotrypsin-like activity of the proteasome, or protein levels of multiple proteasome subunits. Moreover, despite decreases in intramyocellular lipid content, no robust changes in mRNA levels for key proteins involved in insulin signaling, glycolysis, oxidative metabolism, or fat metabolism were observed. Conclusion: These findings suggest that examining the contribution of suppressed mTOR signaling in the loss of muscle mass in late-stage NSCLC patients is warranted and reinforces our need to understand the potential contribution of impaired fat metabolism and muscle protein synthesis in the etiology of cancer cachexia.
Introduction
Cachexia, characterized by the unintended loss of skeletal muscle mass, is common in patients with nonesmall-cell lung cancer (NSCLC), with about one half presenting with severe muscle depletion at diagnosis. 1 Cachexia has been associated with reductions in tolerance to anticancer therapy, quality of life, and survival. 2 Given that no standard treatment exists for cancer cachexia and because it cannot be reversed using conventional nutritional support, it represents a major unmet clinical need. For logical developments in therapy to occur, the physiologic and cellular mechanisms that lead to the loss of muscle mass in these patients need to be better understood.
Although reports of the effect of cancer on muscle metabolism in patient populations have been limited, the evidence accumulated to date has suggested that cancer-induced alterations in muscle metabolism will be reversed by cancer resection. 3, 4 This implicates the cancer burden as a key driver in cancer cachexia. NSCLC, in common with a number of cancers, is associated with increased synthesis and elevated circulating concentrations of pro-inflammatory cytokines, including tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6). 5 Animal and cell culture work has routinely demonstrated inflammation to negatively affect multiple facets of muscle metabolism 6 ; thus, inflammation might act as a central causative feature for the cachexia that develops with cancer progression. In support of this, the administration of an IL-6 receptor antibody to impair the action of IL-6 has been shown to negate 84% of the muscle atrophy typically observed in the gastrocnemius of a murine model of cancer cachexia. 7 The loss of muscle mass is thought to develop as a consequence of enhanced muscle proteolysis, predominantly through activation of the ubiquitin proteasome system (UPS), with concomitant suppression of muscle protein synthesis. 8 Specifically, a reduction in mechanistic target of rapamycin (mTOR) signaling has been reported in the Apc(Min/þ) mouse model of cancer, with hypophosphorylation of the downstream targets p70-S6k and 4E-BP1, 9 which would be projected to lead to reduced initiation of translation. 10 The suppression of mTOR signaling parallels the decrease in muscle protein synthesis and muscle mass in experimental cancer cachexia, 9 and a dose-dependent suppression of IL-6 on mTOR activity has been reported, 11 suggesting it plays a key role. Likewise, a number of studies of animals and patients with various cancers have reported an increase in components of the UPS, [12] [13] [14] including increased transcription of the 2 ubiquitin ligases, MuRF1 (muscle ring finger protein 1) and MAFbx (muscle atrophy F box; atrogin-1), which appear instrumental in the specific targeting of muscle proteins for degradation by the 26S proteasome. 15, 16 Reports of IL-6 receptor antibody administration preventing proteasome activity and muscle atrophy in an experimental model of cancer cachexia, 7 viewed in conjunction with the ability of pharmacologic inhibition of the proteasome pathway to blunt cancer cachexia, 17 have highlighted the central role ubiquitin-proteasomeemediated proteolysis is thought to play in the progression of cancer cachexia. However, of the studies that attempted to examine components of the proteasome pathway in patients with NSCLC, none demonstrated an increase in UPS activity. 5, 18, 19 Thus, the contribution of ubiquitin-proteasomeemediated proteolysis in NSCLC cachexia remains unclear. In addition to the described changes in protein metabolism, cancer-induced alterations in muscle carbohydrate and lipid metabolism could be underpinning the impaired muscle function experienced by cancer patient populations. The development of peripheral insulin resistance has been commonly observed in experimental cancer models and in cancer patients. 20 Inflammation, including by action of the cytokines IL-6 and TNF-a, has been associated with impairment of the AKT insulin signaling pathway. Likewise, administration of IL-6 to healthy individuals to increase plasma IL-6 concentrations leads to profound increases in muscle lipolysis and fatty acid oxidation. 21 However, the effect of late-stage NSCLC on muscle metabolism remains poorly defined. The purpose of the present study was to examine the effect of late-stage NSCLC on inflammatory signaling and key parameters that regulate muscle protein and fat and carbohydrate metabolism to provide unique insight into the potential mechanisms responsible for cachexia and functional impairment in this patient population.
Patients and Methods

Ethical Approval
Research was conducted in accordance with the Declaration of Helsinki (2008) of the World Medical Association regarding the use of human subjects in medical research. The East Midlands Research Ethics Committee approved the study (reference no. 09/H0403/ 65). All the participants were given a full explanation of the study and provided written informed consent.
Participants
The patients were recruited from an existing study examining the effectiveness of an exercise regimen in adults scheduled to receive first-line palliative chemotherapy after a diagnosis of advanced NSCLC. 22 The recruited patients underwent the described protocol before beginning chemotherapy or undertaking the exercise intervention required of the parent study. 22 The patients had an Eastern
Cooperative Oncology Group performance status of 0 to 2. 23 The lumbar computed tomography muscle mass was determined using diagnostic computed tomography images and SliceOMatic analysis software, in accordance with previously described methods. 24 The appendicular muscle mass was determined using dual-energy x-ray absorptiometry (Lunar Prodigy Advanced; GE Healthcare, Chicago, IL) with the accompanying Encore software, version 13.6, using standard imaging and positioning protocols. 25 The mean daily protein (g/day) and energy (kJ/day) intake was calculated using Compeat, version 5.8.0 (Nutrition Systems UK), based on a prospective 3-day diary that included 1 weekend and 2 weekdays. Relevant anthropometric and blood pathology results were obtained from the patients' medical records. Healthy volunteers of a similar age, gender, smoking history, and physical activity level to the patient group and without a history of metabolic or cardiovascular disease or vegetarian diet were recruited ( Table 1 ). The healthy volunteers underwent a battery of blood tests, including full blood count, liver function tests, and urea and electrolytes, with all values within the normal range. The physical activity level was matched using the 12-item modified Baecke questionnaire, 26 which summarizes the habitual physical household (eg, housework, meal preparation, and stair climbing) and leisure activities in the previous year. The questionnaire was selected because it has been shown to be a valid and repeatable assessment of physical activity, suited to the older population, and has previously been used to match volunteers to NSCLC patient groups. 27 
Study Protocol
The participants attended the laboratory facility at 9:00 am after an overnight fast and having abstained from alcohol and vigorous exercise the previous day. With the participant resting in a semisupine position, a venous blood sample was taken from a vein in the antecubital fossa region into prechilled ethylenediaminetetraacetic e2 -Clinical Lung Cancer January 2017
Late-Stage NSCLC Cachexia acid tubes. The samples were kept on ice and within 30 minutes of collection were centrifuged at 3000g for 10 minutes, with the resultant plasma stored at À80 C before analysis. Next, a single percutaneous muscle biopsy specimen was obtained from the vastus lateralis muscle under local anesthetic according to the method described by Bergstrom. 28 The muscle sample was snap frozen and stored in liquid nitrogen before quantitative polymerase chain reaction (qPCR) and western blot analysis.
Plasma IL-6 and TNF-a Concentration by EnzymeLinked Immunosorbent Assay
The cytokines TNF-a and IL-6 are both known to be systemically elevated in a multitude of cancers, including in NSCLC. 5 To determine the changes in systemic circulating levels of IL-6 and TNF-a in NSCLC patients, the protein concentrations of both cytokines were examined in plasma samples using commercially available enzyme-linked immunosorbent assays (Arcus Biologicals, Modena, Italy). The samples were run in duplicate with standards of known concentration according to the manufacturer's protocol. At the end of the assay, the absorbance at 450 nm was determined for each well of the enzyme-linked immunosorbent assay plate using a spectrophotometer (Molecular Devices, Sunnyvale, CA).
Quantitative PCR
Total RNA was extracted from 30 mg of muscle tissue using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Waltham, MA) and quantified on a nanoDrop spectrophotometer. cDNA was subsequently synthesized using the SuperScript III commercial cDNA synthesis kit (Invitrogen), according to the manufacturer's protocol. Low-density microfluidic cards containing PCR primer pairs and Taqman probes for a number of regulatory genes associated with carbohydrate, fat, and protein metabolism were used and analyzed on a 7900 HT Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific). MAFbx and MuRF1, 2 ubiquitin ligases that appear central to muscle atrophy in a number of cachectic states, 16 EuroFins Scientific (Luxembourg). Hydroxymethylbilane synthase was also represented on the microfluidic cards and was used as a housekeeping gene throughout the 2 qPCR approaches adopted. Relative quantification of MAFbx, MuRF1, and myostatin was performed on an ABI Prism 7000 Sequence Detection System (Applied Biosystems). The obtained data were analyzed using the comparative Ct method ( DD Ct) for the relative quantification of gene expression. No significant difference was observed between the groups for cycle threshold values of the housekeeping gene (data not shown).
Western Blotting
Given the essential role of mTOR signaling in the control of muscle protein synthesis, and the UPS in eliciting enhanced muscle proteolysis in a number of cachectic states, both were examined by western blot analysis in tandem to assess their effect on the regulation of muscle mass. In brief, cytosolic proteins were extracted from 30 mg of muscle tissue, quantified, separated by molecular weight on a 4% to 12% Bis-Tris polyacrylamide gel by electrophoresis, and transferred to PVDF membranes (Amersham Biosciences; GE Healthcare Life Sciences, Little Chalfont, UK) using methods previously described in detail. 29 The membranes were subsequently blocked with 5% (wt/vol) bovine serum albumin in 1Â Tris-buffered saline for 1 hour, followed by incubation overnight with a primary polyclonal antibody for AKT, mTOR, GSK3b, 4E-BP1, or p70S6K (Cell Signaling Technology Inc., Danvers, MA) or proteasome subunits a1-3; a5-7 (Biomol, Hamburg, Germany). The following phospho-specific primary antibodies were also used: AKT Thr 308 , mTOR Ser 2448 , GSK3b Ser 9 , 4E-BP1 Ser 65 , and p70S6K Thr 389 (Cell Signaling Technology).
After incubation with the primary antibody and subsequent washing in Tris-buffered saline-Tween 20, the membranes were incubated with a fluorescent-labelled anti-mouse or anti-rabbit secondary antibody as appropriate (Dylight conjugate; Cell Signaling Technology) before digital capture on an electronic image acquisition system (Odyssey CLx; LI-COR Biosciences, Lincoln, NE). Band densities were determined using the proprietary software provided with the Odyssey scanner and normalized to b-actin (SigmaAldrich, Dorset, UK) protein levels to control for loading.
26S Proteasomal Activity
Proteasomal activity was measured using a method adapted from Dawson et al 30 and Kisselev et al. 31 In brief, 20 mg of muscle tissue was homogenized for 2 minutes with a glass-ground homogenizer in a 1:20 volume of extraction buffer (50 mM Tris-HCl [pH 7.5], 5 mM MgCl 2 , 2 mM ATP, 1 mM DTT, and 0.5 mM EDTA). Next, the sample was centrifuged at 8000g for 20 minutes at 4 C. From the supernatant, 5 mL was assayed for proteasomal activity in 400 mL of assay buffer (50 mM Tris-HCl [pH 7.5], 40 mM KCl, 5 mM MgCl 2 , 0.5 mM ATP, 1 mM dithiothreitol, and 0.5 mg/mL bovine serum albumin) by the addition of 4 mL of a 10-mM solution of the fluorogenic substrate Suc-LLVY-amc (Sigma-Aldrich), followed by incubation for 10 minutes at 37 C. After the allotted time, the reaction was stopped by the addition of 1.6 mL of an 80-mM potassium acetate solution (pH 4.3). Emission at 460 nm of the cleaved substrate was determined on the resultant solution using a fluorometer (F-2000; Hitachi High Technologies, Tokyo, Japan) after excitation at 360 nm. Analysis of a duplicate sample treated in the same manner as above but including the proteasome-specific inhibitor epoxomicin (20 mM; Sigma-Aldrich) in the reaction mixture completely prevented cleavage of the fluorogenic substrate, confirming specificity of the reaction for proteasomal-dependent proteolysis.
Pyruvate Dehydrogenase Complex Activity
Approximately 5 mg of snap-frozen muscle that had remained stored under liquid nitrogen conditions was assayed for pyruvate dehydrogenase activity (PDCa) using an established radioisotopic assay. 32 PDCa was expressed as the rate of acetyl-coenzyme A (CoA) formation (mmol/min at 37 C) normalized for the protein content in the biopsy specimens.
Assessment of Intramyocellular Lipid Content
To establish whether chronic and gross changes in muscle fat metabolism had occurred with NSCLC, the percentage of area occupied by lipid droplets in the muscle fibers was examined.
Frozen muscle was sectioned (10 mm) and fixed in 4% paraformaldehyde phosphate-buffered saline (pH 7.4) before assessment of the intramyocellular lipid (IMCL) content using the lipophilic dye, LD540 (synthesized by the University of Nottingham School of Chemistry 33 ). To accomplish this, the sectioned samples were incubated at room temperature for 1 hour with 3 mM LD540 in dimethyl sulfoxide, followed by 3 washes in phosphate-buffered saline before being embedded in an antifade reagent (ProLong Gold; Life Technologies, Paisley, UK). LD540-stained lipid droplets were visualized at 40Â magnification as 1-mm z-stacks with the aid of a 561-nm laser coupled to a TCS SP2 confocal microscope (Leica Microsystems, Heidelberg, Germany). The area of the fiber covered by fluorescence was calculated using the commercial Volocity software package, version 6.3 (PerkinElmer, Cambridge, UK), and the fiber type was identified by staining with an antibody raised against the human adult form of slow myosin heavy chain (A4.951; developed by Dr. Blau). 34 The Volocity software was used to calculate the intramuscular lipid content normalized to the fiber area on a fiber-typeespecific basis.
Statistical Analysis
The small sample sizes used in the present study are common in basic science studies requiring the use of invasive muscle sampling techniques in chronically ill small patient populations (eg, Chen et al 35 and Madsen et al 36 )
. As such, between-group comparisons were performed using an unpaired t test, because it has been previously demonstrated that the t test is a valid approach and outperforms the nonparametric Welch test when small sample sizes are used. 37 Similarly, given the number of patients recruited, correcting the qPCR data for multiple comparisons would lead to an increased incidence of type II errors, masking the genuine gene expression changes. As such, data are reported uncorrected. Instead, potential type I errors were considered informally at the level of interpretation by considering the changes across the spectrum of genes analyzed, a valid approach when performing multiple comparisons. 38 All statistical tests were performed using the Prism, version 6.02, statistical software package for Windows (GraphPad Software Inc., San Diego, CA), with data reported as the mean AE standard error of the mean and statistical significance accepted at P .05.
Results
Demographic Data and Other Details
The characteristics of the patient and control subjects are described in Table 1 2 ). Moreover, patients had lost a mean of 9% AE 2% of their body weight during the preceding 6 months. Compared with the healthy volunteers, the patients with NSCLC had a lower body mass index and activity levels, but the differences were not statistically significant. The latter is perhaps not surprising, given the wellreported issues faced with obtaining accurate self-reported measures of physical activity. 39 Analysis of the dietary intake revealed patients with NSCLC to have a positive protein balance (38 AE 21 g/ day) and a calorie intake marginally under the predicted requirements (À72 AE 241 kJ/day). Given that a notable proportion of patients with late-stage lung cancer fail to experience cancer anorexia (> 35%) 40 and that these patients were fit enough to undergo subsequent palliative chemotherapy, the general ability of NSCLC patients to mostly maintain their protein and calorie intake is not perhaps surprising. The median survival time of patients from the time of their study visit was 23 weeks (range, 15-35 weeks).
Systemic Cytokine and Muscle Inflammatory Marker Levels
Compared with healthy volunteers, patients with NSCLC had a significantly greater plasma IL-6 concentration and exhibited a trend toward increased plasma TNF-a concentrations (P ¼ .07; Figure 1A and B). Because skeletal muscle can also be a significant source of IL-6
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and TNF-a production, either from invading neutrophil and macrophage cell populations or the muscle cells themselves, 27 we also determined the expression of IL-6 and TNF-a mRNA within the muscle biopsy specimens. Compared with the healthy control subjects, the patients with NSCLC had a statistically significant 2.6-fold increase in IL-6 muscle mRNA expression ( Figure 1C) . However, the TNF-a mRNA levels were equivalent between the 2 groups. NSCLC was also associated with significantly greater mRNA levels for the examined components of the NF-kB pro-inflammatory signaling pathway, NF-kB1 and NF-kB3 (RELA). The mRNA levels of the NF-kB signaling pathway inhibitor, IkK-a, was also greater in the muscle specimens from the NSCLC patients.
Muscle Protein Metabolism and Regulation of Muscle Size
Compared with the healthy volunteers, lower mTOR protein and Ser 2448 phosphorylation levels were observed in the patients with NSCLC. However, the difference was not statistically significant ( Figure 2A ), with no difference in phosphorylation state (phosphorylation to total protein) observed between the 2 groups. In contrast, the phosphorylation state of residue Ser 65 of the downstream protein 4E-BP1 was significantly lower in the muscle of the NSCLC patients ( Figure 2B ), together with a trend toward lower p70 S6K Thr 389 phosphorylation (P ¼ .07; Figure 2C ). No significant differences were found in the 4E-BP1 and p70 S6K muscle protein levels between the NSCLC patients and healthy controls ( Figure 2B and C, respectively). The mRNA levels of MAFbx, MuRF1, and myostatin did not differ between the NSCLC patients and the control subjects ( Figure 2D ). In keeping with the failure of NSCLC to enhance MAFbx and MuRF1 expression, the protein levels of the a1-3 and a5-7 subunits of the proteasome and chymotrypsin-like activity of the 26S proteasome were unaltered in the muscles of the patients with NSCLC ( Figure 2E and F, respectively).
Insulin Signaling and Carbohydrate Metabolism
Examination of mRNA levels for several components of the insulin signaling pathway revealed NSCLC was associated with significantly enhanced levels of both AKT and GSK-3b in the muscle of the affected patients ( Figure 3A) . However, this did not translate into changes at the total protein level. The muscle samples from the NSCLC patients displayed significantly lower levels of AKT protein compared with the healthy volunteers ( Figure 3B ). However, the absolute phosphorylation levels of AKT at residue Thr 308 did not differ between the 2 groups. Thus, the phosphorylation state of AKT was significantly increased. Similarly, the protein level of the downstream kinase GSK3b was equivalent between the NSCLC patients and control subjects ( Figure 3C ). However, on determination, a significant increase in the phosphorylation state of GSK3b in the NSCLC patients was observed, despite similar degrees of absolute phosphorylation between the 2 groups. Similarly, no differences were observed in the mRNA levels of several genes intimately associated with carbohydrate metabolism ( Figure 4A ) or oxidative metabolism ( Figure 4B ). In further support, the rates of muscle PDCa, a pivotal regulator of acetyl-CoA formation from pyruvate for use by the Krebs cycle, was comparable between the groups ( Figure 4C ).
Fat Metabolism
NSCLC was associated with a lower area of the muscle fiber occupied by lipid in the slow-twitch, but not the fast-twitch, muscle fibers ( Figure 5A ; P < .05). However, with the notable exception of long-chain acyl CoA synthetase, for which increased mRNA levels were observed ( Figure 5A ), late-stage NSCLC was not associated with alterations in the expression of multiple key genes associated with the regulation of fat metabolism ( Figure 5C ).
Discussion
The effect of late-stage cancer on muscle metabolism in patients remains largely unknown. In the present study, we have demonstrated for the first time that in stage IV NSCLC patients with cachexia and increased plasma IL-6 concentrations, only modest changes in key transcriptional and signaling events underpinning carbohydrate, fat, and protein metabolism are observed. Moreover, these changes do not explain the pronounced cachexia or decreased muscle lipid accumulation seen in these patients, reinforcing the essential need to initiate treatments aimed at preventing cachexia early in the disease process before cachexia becomes evident. It has been suggested that hypermetabolism and activation of muscle proteolytic pathways are confined to the early stages of the disease 41 and will resolve on removal of the tumor burden. 3, 4 Our results are in agreement with the proposed dynamic nature of cancer cachexia and provide the first insight that the latter stages of NSCLC do not appear defined by substantial changes in muscle metabolism, despite the prevalence of systemic and localized markers of inflammation. Our findings have thus demonstrated the complex interplay that exists between the tumor burden and metabolism in distal tissues, which also likely changes over time.
Although myostatin acts as a negative regulator of muscle mass, 42 we could find no evidence that its expression was altered in the muscle samples from late-stage NSCLC patients; a finding that is in keeping with the reports from studies of both lung 43 and gastric cancer patients. 43, 44 Likewise, our inability to detect any indication of increased UPS-mediated proteolysis corroborates the findings from recent reports that MuRF1 and MAFbx are not elevated in late-stage NSCLC cachectic patients. 19 Also, multiple reports have failed to identify any traditional indicator of increased muscle proteasome-mediated proteolysis in NSCLC patients at various stages of cachexia. 5, 18 In contrast, although gastric cancer patients undergoing tumor resection have shown basal levels of atrophy gene expression compared with patients undergoing abdominal surgery for benign disease, 44, 45 other markers of UPS activity appear increased and, moreover, dependent on the degree of cachexia present. 12 Collectively, this evidence suggests that the recruitment of proteasome-mediated proteolysis might be specific to certain cancer types or clinical scenarios (eg, when cancer-induced anorexia is evident). Although ubiquitin proteasome-mediated proteolysis has generally been considered the principal mechanism by which muscle atrophy proceeds in cachectic states (see Murton et al 46 ), our findings do not preclude proteolysis occurring by an alternative route. Indeed, previous observations 5 of increased transcription of proteases involved in lysosomal-mediated protein breakdown in the muscle of lung cancer patients highlights the need to consider more widely the processes by which atrophy is occurring in NSCLC patients. An alternative mechanism that might contribute to the loss of muscle mass during NSCLC is suppression of muscle protein synthesis by inhibition of mTOR signaling, with mTOR acting as a nutrient sensor activating muscle protein synthesis during periods of nutrient availability. 47 In patients with NSCLC, reductions in mTOR protein and phosphorylation levels were observed, in addition to reduced p70 S6K and 4E-BP1 phosphorylation, albeit only for the latter was the difference statistically significant. The collective consequences of reduced p70 S6K and 4E-BP1 phosphorylation would be a reduced drive for muscle protein synthesis. 48 However, reports that acute mTOR inhibition by rapamycin administration does not affect the postabsorptive rates of muscle protein synthesis in healthy humans 49 questions the effect of the observed reduction in mTOR signaling on the induction of cachexia. In contrast, given the essential role of mTOR in eliciting increases in muscle protein synthesis during hyperaminoacidemia 49 or after contractile activity, 50 if reductions in mTOR activity persisted after meal consumption or physical activity, it would be anticipated to lead to pronounced blunting of the protein synthetic response in NSCLC patients. Recent evidence from a feeding study of patients with operable colorectal cancer provides credence for this suggestion, because the provision of amino acids was seen to stimulate muscle protein synthesis in healthy age-matched controls but not in the patient population. 4 Likewise, similar observations have been seen in cachectic cancer patients during intravenous protein provision. 51 Collectively, these findings highlight the pressing need to understand the metabolic response to feeding and physical activity in NSCLC patients and whether it persists into the late stages of the disease. In many cancers, the catabolism of body fat reserves is common and occurs in response to the potential declines in food intake concomitant with hypermetabolism. 52 Despite the high occurrence of fat catabolism in cancer patient populations, the effect of cancer on human muscle fat metabolism or muscle lipid accumulation is poorly understood. In the present study, we have shown that latestage NSCLC is associated with a significant reduction in lipid accumulation in slow-twitch fibers, where oxidative metabolism of fatty acids is likely to dominate. Moreover, in the absence of a robust induction of transcriptional events previously associated with 53 it reinforces the notion that gross changes in fat metabolism occurred early in the disease process and had been rectified at the time of study participation, with decreased lipid accumulation acting as a remnant of earlier changes. Given the low subject numbers included in the present study, some caution must be applied to this finding because of previous reports of increased intramyocellular droplets in rectus abdominis muscle being associated with cancer cachexia, 54 in contrast to the observations we have reported. However, their use of gastrointestinal cancer patients in conjunction with patients undergoing elective surgery as control subjects, the use of a nonambulatory muscle for examination, and their failure to control for age (it is well-known that IMCL increases with age) between the subject groups makes any direct comparisons difficult. Nevertheless, a clear relationship was found between the loss of fat mass and increased IMCL, 54 suggesting a lipolysis-mediated imbalance between skeletal muscle fatty acid delivery and oxidation. The later stage cancer, lower body mass index, and reduced IMCL in the patients included in the present study would thus suggest that skeletal muscle fatty acid oxidation has outweighed delivery and the muscle is in a state of overt undernutrition. It appeared that PDCa was lower in the face of greater PDK4 mRNA expression, which would fit with skeletal muscle undernutrition and insulin resistance, although the difference failed to reach statistical significance. 55 In common with a number of disease states in which chronic inflammation and IMCL accumulation is evident, cancer has been associated with the development of insulin resistance, 20 thereby affecting carbohydrate metabolism in the peripheral tissues. To date, despite the potential contribution to muscle fatigue, a comprehensive evaluation of the effect of late-stage NSCLC on muscle carbohydrate metabolism remains unexplored. Although no index of insulin sensitivity was assessed in the present study and the subject 
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Clinical Lung Cancer January 2017 -e9 numbers were small, increasing the probability of type II errors, NSCLC failed to show a consistent effect synonymous with insulin resistance on insulin signaling or transcriptional regulation of the key genes involved in glycolysis or oxidative metabolism. This would perhaps fit with the lower IMCL. Notably, these observations were made with the subjects in the fasted state, and further research is required to establish whether NSCLC has an effect when the subjects are in the postprandial state to determine whether insulin resistance coincides with anabolic resistance.
Study Limitations
Although the data reported provide a unique insight into the metabolic consequences of late-stage NSCLC on muscle, they are the result of observations obtained from a limited number of patients. Nonetheless, our findings highlight important features of NSCLC-related cachexia worthy of further investigation and identify several gaps in our understanding. Given our findings, future work should consider examining NSCLC patients with and without cachexia and incorporating detailed measures of muscle metabolism using robust stable-isotope methods, although the additional invasive nature of the procedures and the prolonged laboratory visits required, might represent additional challenges to the recruitment of patients with advanced cancer.
Conclusion
Our findings provide insight into the metabolic changes evident in skeletal muscle during late-stage NSCLC and contribute to the mounting evidence that the UPS does not play a primary role in the loss of muscle mass in NSCLC patients. Moreover, our findings highlight the need for greater understanding of the contribution of impaired fat metabolism and muscle protein synthesis in the etiology of cancer cachexia.
Clinical Practice Points
The loss of muscle mass is a common consequence of NSCLC, which can substantially affect a patient's quality of life and their ability to adhere to prescribed chemotherapy. A significant number of patients will be diagnosed in the later stages of disease, when weight loss and muscle atrophy have already been established. Despite this, the effect of late-stage NSCLC on muscle metabolism and the associated mechanisms are largely unknown but represent a crucial prerequisite for the development of effective treatments against cachexia in these patients. Based on work performed in animal models of cancer cachexia, it would be anticipated that the loss of muscle mass during NSCLC largely results from the enhanced rates at which muscle proteins are broken down by increased UPS activity. In stark contrast, our present report has demonstrated that blunted mTOR signaling, an essential pathway for driving the synthesis of new muscle protein, is reduced in the muscle of NSCLC patients and is a likely culprit for the loss of muscle mass in these patients, with the markers of the UPS activity remaining unaltered. Furthermore, we provide the first evidence that late-stage NSCLC is associated with a reduced intramyocellular lipid content, the consequences of which remain to be characterized.
Collectively, these observations reinforce the notion that treatments aimed at reducing cachexia during late-stage NSCLC should focus on restoring the cellular processes responsible for promoting the synthesis of muscle proteins. Speculatively, the combination of resistance exercise and protein supplementation might represent one such strategy.
